Objective: To determine whether dose titration based on therapeutic response is superior to standard dosing of oral trospium chloride in patients with neurogenic detrusor overactivity and, moreover, to investigate the possible underlying causes of differences in efficacy at equal doses in some patients. Patients and methods: Using a double-blind approach, two groups (standard dose and adjustable dose) with a total of 80 patients were treated with trospium chloride coated tablets for a period of 3 -5 weeks.
Trospium chloride in patients with neurogenic detrusor overactivity Abstract. Objective: To determine whether dose titration based on therapeutic response is superior to standard dosing of oral trospium chloride in patients with neurogenic detrusor overactivity and, moreover, to investigate the possible underlying causes of differences in efficacy at equal doses in some patients. Patients and methods: Using a double-blind approach, two groups (standard dose and adjustable dose) with a total of 80 patients were treated with trospium chloride coated tablets for a period of 3 -5 weeks. Treatment duration and daily doses varied depending on change of urodynamic parameters defined as therapeutic response. In Week 1, both groups started on 45 mg/day (3 × 15 mg). In the adjustable dose group, it was permissible to increase the daily dose to 90 or 135 mg/day depending on the urodynamic treatment response. In contrast, doses remained unchanged in the standard dose group although a need for dose adjustment had been recognized under the double-blind conditions. Therapeutic response was defined as improvement of at least two of the following three urodynamic parameters: bladder compliance ³ 20 ml/cmH 2 O, maximum cystometric capacity > 250 ml and maximum detrusor pressure £ 40 cmH 2 O. Changes in individual urodynamic parameters were defined as secondary efficacy variables. Primary and secondary parameters were assessed by comparing baseline values with those at the end of treatment. Therapeutic response was analyzed by using the FisherYates test, and the Mann-Whitney U-test was used for secondary parameters. Trospium plasma concentration was measured to assess patient's compliance and as a tool to elucidate possible factors influencing treatment efficacy. Safety and tolerability were evaluated based on withdrawal rates and adverse events. Results: Both dose groups had comparable baseline characteristics. Therapeutic response was achieved in 58% of patients in the adjustable dose group (ADG) and in 72% of those in the standard dose group (SDG, p = 0.23). Clinically relevant increases in maximum cystometric capacity and bladder compliance were observed, and there was a clear decrease in detrusor pressure. After Day 7, the daily dose was increased in 52.8% of all patients in the adjustable dose group and (seemingly) in 32.5% of those of the standard dose group. Further dose escalation after Day 14 was assessed as necessary in 15% of the standard dose group and 22% of the adjustable dose group. The main changes in urodynamic parameters occurred during the first 7 days of treatment, but in some patients it takes a longer time. No statistically significant differences between plasma trospium chloride levels in the two dose groups were observed at any time, but increase of plasma concentration with higher doses became obvious when patients were differentiated to individual dose stages. In both groups, the most common treatment-related adverse event was dry mouth (ADG 35%, SDG 37%), which never led to discontinuation of treatment. Rates of other adverse events such as dry skin, dysopia, increased heart rate and gastrointestinal disorders were much lower. Conclusion: Generally, in patients with neurogenic detrusor overactivity daily doses of 45 mg trospium chloride can be considered as being the standard dose, and dose adjustment, e.g. due to increased body weight, might usually not be necessary. However, increased daily doses of up to 135 mg appear to be safe when prescribed in individual patients less responsive to the drug.
Introduction
Overactive bladder (OAB) is a common and disabling condition with a considerably negative impact on quality of life, quality of sleep, and mental health. It impedes the completion of everyday tasks and affects social, psychological, physical, sexual, domestic and occupational behaviors [Kelleher 2002 , Luscombe 2000 , Tubaro 2004 ]. This highly prevalent global condition affecting millions of people worldwide is associated with profound economic costs [Luscombe 2000, Wein and Rovner 2002] . Although OAB can affect anyone at any age, its prevalence tends to increase with age.
Anticholinergic drugs are the most effective agents for OAB treatment today [Andersson et al. 2005] . Especially in the urothelium, the M2 receptor subtype seems to play an important role in the development of OAB symptoms, whereas the M3 receptor may be mainly involved in physiological detrusor contraction Schröder 2004, Hedge et al. 2004] . Ideally, anticholinergics used in overactive bladder treatment should, therefore, have a high affinity for both receptor subtypes.
Individual dose titration is a common strategy for achieving the maximum tolerable dose of anticholinergic drugs in OAB treatment [Staskin and MacDiarmid 2006] . The optimal individual dosage is determined by weighing the efficacy of therapy against the intensity of adverse events. In the case of oxybutynin [Bennett et al. 2004 , Davila et al. 2001 , Miller et al. 2000 , emepronium carrageenate [Massay and Abrams 1986] , darifenacin [Steers et al. 2005 ] and, with restrictions, solifenacin, this strategy appears to benefit certain patients [Chapple et al. 2004a [Chapple et al. , 2004b . However, tolterodine's dose range for optimal efficacy and tolerance is very limited [Clemett and Jarvis 2001, Rentzhog et al. 1998 ].
In the case of trospium chloride, urologists sometimes recommend individual dose adaptation often exceeding the regular daily dose of 45 mg, especially in patients with neurogenic detrusor overactivity. A first placebo-controlled dose-finding study indicates dose-dependent effects on detrusor contraction, cystometric bladder capacity and improvement of symptoms in the range of 20 -80 mg oral trospium chloride/day in patients with neurogenic detrusor overactivity [Stöhrer et al. 1998 ]. Therefore, the objective of this double-blind study was to determine whether individual dose adaptation based on therapeutic response is superior to standard dosing of oral trospium chloride in patients with neurogenic detrusor overactivity. Possible underlying causes of differences in efficacy at equal drug doses in some patients were also investigated, e.g., differences in interindividual pharmacokinetics, body mass and other factors.
Patients and methods
This EC-GCP conform double-blind, randomized, actively controlled, parallel-group clinical trial was carried out in 10 centers in Argentina, Austria, Chile, Germany, Italy and Switzerland in accordance with the Revised Declaration of Helsinki and with local laws and regulations. Each participating center's Ethics Committee approved the final study protocol and the consent forms in writing before the start of the study.
A total of 80 patients with neurogenic detrusor overactivity (proven spontaneous detrusor contractions of at least 15 cmH 2 O), aged ³ 18 years and £ 70 years were recruited after giving their written informed consent to the study. To be included, the patients had to have a traumatic complete or incomplete spinal cord lesion between segments C2 and T12, and reflex arches between segments S2 and S4 had to be intact. Patients also had to fulfil at least two of the following urodynamic criteria: bladder compliance < 20 ml/cmH 2 O, maximum cystometric capacity £ 250 ml, maximum detrusor pressure > 40 cmH 2 O. These values had been defined in the protocol as upper/lower limits of normal bladder storage. Furthermore, only patients who emptied their bladder by intermittent catheterism were eligible to participate.
Patients with contraindications to anticholinergic therapy (narrow-angle glaucoma, gastrointestinal stenosis, myasthenia gravis, urinary retention, etc.) were excluded from enrolment. Other exclusion criteria were other types of urinary dysfunction, urinary tract infection at the screening visit and during treatment, anticholinergic pre-or comedication 7 days before or during the study (including drugs with significant anticholinergic effects, e.g. antihistamines) and hypersensitivity to trospium chloride coated tablets. Other clinically significant diseases, pregnancy, lactation, alcohol abuse, drug abuse, tachycardia, severe psychiatric disease and participation in another study during the last 30 days were further reasons for exclusion from the study.
Study design
Screening consisted of history-taking, a physical examination including measurement of blood pressure and heart rate, and clinical laboratory tests. In addition, bladder status was evaluated radiologically. Before baseline urodynamic test, patients had to enter a 7-day washout period if required. Urodynamic investigations were carried out under standardized conditions (identical position in each investigation, 8 Charr. double-lumen perfusion catheter, 10 Charr. balloon rectal tube, filling medium: isotonic saline solution 35 -37°C, filling rate < 20 ml/min) in accordance with the relevant ICH-and EAU Guidelines [Stöhrer et al. 1999 [Stöhrer et al. , 2003 .
Patients were randomly assigned to 1 of 2 treatment groups. In order to enable double-blind conditions, dose adjustments were allowed only after Days 7 and 14 of treatment. Patients in the control group (standard dose group, SDG) received fixed daily doses of 45 mg trospium chloride (Spasmex ® 15 mg coated tablets; Dr. R. Pfleger GmbH, Bamberg, Germany) throughout the entire study period even if investigators decided for dose adjustment. In the adjustable dose group (ADG), the standard daily dose could be adjusted to 90 mg/day (3 × 30 mg) or 135 mg/day (3 × 45 mg) after Days 7 and 14, depending on the therapeutic response. Appearance of the coated tablets, packaging and labeling in the SDG did not differ from those of the ADG. In both groups, packages assigned to different grades of dosing were labeled with A, B and C. Consequently, patients and clinical investigators believed that dose could be increased in the SDG, too. In the case of dose adjustment, medication of the previous grade was collected from the patient, before packages of the next grade were handed over. Patients were instructed on drug intake (1 tablet in the morning, at midday and in the evening each/ day, to swallow whole with water, no instructions concerning relation to food intake) and patient's compliance was checked by counting the returned tablets, monitoring trospium chloride plasma levels and by investigating physician's evaluation.
Therapeutic response was defined as improvement of at least two of three urodynamic parameters, i.e. bladder compliance: ³ 20 ml-/cm H 2 O, maximum cystometric capacity: > 250 ml, maximum detrusor pressure: £ 40 cmH 2 O. If therapeutic success was achieved, in both groups the daily dose remained the same as in the period before. Study course and times of change of daily dose are depicted in Figure 1 . The duration of treatment ranged from 3 -5 weeks depending on the time of assignment of the final daily dose.
Therapeutic response, the main efficacy variable, was determined urodynamically as the change in bladder storage from baseline until the end of treatment (5 weeks maximum). Changes in individual urodynamic parameters were investigated as secondary efficacy variables comparing pre-and post- treatment values. Safety and tolerability data were obtained at each visit to the clinic (frequency see Figure 1 ) and at any time when voluntarily reported by the patient. Furthermore, on each day of urodynamic testing ( Figure 1 ), blood samples were collected between 8:00 and 10:00 a.m. in order to determine trospium chloride levels in plasma. Plasma concentrations of trospium were measured by using a validated GC-MS method. In addition, blood concentrations were calculated relative to body weight, height and body surface area, in order to investigate possible influence of these characteristics on blood levels. The patients' general subjective rating of OAB symptoms and the number of incontinence episodes per day during treatment period were also documented at each visit.
Statistical analysis and quality assurance
For sample size determination, it was assumed that dose adaptation would be necessary in approximately 50% of the patients. Therapeutic success was expected in 90% of the patients receiving optimal dose adjustment. Sample size was calculated using a 2-sided alternative hypothesis. Using a = 0.05 and a power of 1-b = 0.9, the estimated number of patients varied between 61 and 116 (initially planned) depending on the difference in the probability of therapeutic response between both groups.
Patients were randomized into balanced blocks of variable size (1 : 1).
The primary population was the full analysis set (n = 76) comprising all patients randomized, treated and dually efficacy-assessed (both in the pre-treatment period and at least once post randomization). In cases where the corresponding post-treatment value was missing, the efficacy parameters were analyzed using the last-value-carried-forward method. The missing at random assumption was reasonable. The per-protocol set (n = 41) was also analyzed for efficacy parameters, and data sets for all 80 patients were included in the safety analysis.
For quality assurance, each urodynamic test record was audited by an independent specialist. Primary efficacy variable defined as described above was chosen in order to avoid multiple testing of parameters dependent on each other. The incidence of therapeutic success in both groups was analyzed using the Fisher-Yates test as a 2-sided incidence test for categorized data. Values of cystometric bladder capacity and detrusor pressure were dichotomized due to methodological reasons. Secondary efficacy parameters were descriptively evaluated and analyzed using non-parametric tests for two independent samples (Mann-Whitney U-test). Incidences of adverse events in both groups were compared using the Mann-Whitney U-test.
Results
The two groups had comparable demographic characteristics (Table 1) and comparable hematological, biochemical and cardiovascular parameters at baseline. 4 of the 80 patients were excluded from the full-analysis set (FAS) due to the unfeasibility of continuing the efficacy assessment (3 patients with urinary tract infection at time of first intermediate examination and consequently with no data post randomization, 1 patient with inadequate medication compliance). The Safety Analysis Set comprised 80 patients. Altogether, 61 patients received 3 × 15 mg trospium chloride, 11 received 3 × 30 mg after dose adjustment and 8 received 3 × 45 mg af- ter dose titration. The total treatment duration ranged from 3 -5 weeks depending on the dose level. Each patient received the final dose over a period of 21 days. The two groups' mean baseline values for maximum cystometric capacity, maximum detrusor pressure and bladder compliance did not differ in the FAS (Table 2 ) and in the per-protocol set. During treatment, mean maximum cystometric capacity and bladder compliance clearly increased, and detrusor pressure decreased in both dose groups. The extent of these changes, which did not differ between the two groups, was judged to be clinically relevant compared to the range of normal values, especially in maximum bladder capacity [Braun and Jünemann 2004] . Change in the three urodynamic parameters is synonymous with a clear improvement of the bladder storage situation. At the end of the treatment period, therapeutic success (improvement of 2 of the 3 urodynamic parameters) was achieved in 58% of patients in the adjustable dose group and in 72% of those in the standard dose group (FAS). The difference between the two groups was not significant (p = 0.23) (Figure 4 ).
In the standard dose group, daily doses were assessed as in need of being increased after Day 7 due to insufficient improvement of the bladder storage situation in 32.5% of all patients treated (n = 13) compared to 52.8% (n = 19) in the adjustable dose group. After a further 7 days of treatment (Week 2), a second dose increase was considered to be necessary in 15% of patients in the standard dose group (n = 6), and in 22.2% (n = 8) of those in the adjustable dose group. A major mean change in the main efficacy variable occurred during the first 7 days of therapy, and no significant differences between groups were detected at any time (Figure 2) .
On closer examination of the main efficacy variable, it becomes obvious that some patients in both dose groups and at all dose levels showed no adequate post-treatment improvement of bladder storage (Figure 3) . However, no general trend to requiring doses higher than 45 mg/day can be deduced from these results. On the other hand, these results do not exclude that increasing the daily dose according to therapeutic response may be of benefit to individual patients. During the study, the main change in bladder capacity occurred in the first 7 days of treatment ( Figure 5 ). Bladder capacity increased by 46% in the adjustable dose group and by 66% in the standard dose group compared to baseline. The mean change in maximum detrusor pressure was 30% in the adjustable dose group and 42% in the standard dose group, whereas bladder compliance increased by 31% and 20%, respectively.
Statistical analysis of the per-protocol population demonstrated comparable effects in both dose groups as well as in the FAS.
In the standard dose group, trospium chloride plasma levels remained unchanged during the study. However, in the adjustable dose group, mean plasma levels increased slightly from Day 7 to Day 14 of treatment, but there were no significant differences between the two groups ( Figure 6 ). When blood concentration values are differentiated for dose grades, tendency to increased plasma levels becomes obvious with higher doses ( Figure  7 ).
In order to detect possible correlations between the extent of individual plasma levels and body weight, height or surface area, the respective ratios were calculated. Significant influences of these measures on the trospium chloride plasma levels were not detected in either the standard (SDG) or adjustable dose group (ADG).
Patients in both groups reported comparable reduction of bladder symptoms, and the number of patients with incontinence episodes decreased from 92 -53% in the ADG and from 90 -50% in the SDG. Difference between the groups was not significant at any visit. . Trospium chloride plasma levels in the FAS 1 and 2 weeks after the start of treatment and at the final visit (mean ± standard error mean). MannWhitney test (two-tailed) after 7 days: p = 0.82, after 14 days: p = 0.06, at final visit: p = 0.13. Mean values after 7 days are from 35/39 patients (ADG/SDG) all receiving daily doses of 45 mg/day. In the ADG, the value at Day 14 is based on data from 18 patients receiving 90 mg/day and at the final visit, this mean value includes the plasma levels of patients from all 3 dose stages.
In the FAS, 7 patients, 3 in the ADG and 4 in the SDG, discontinued treatment prematurely. One patient in each group dropped out because of adverse events (dysopia). One of these patients complained of persistent constipation. No life-threatening adverse events occurred in either group. Overall, 42 patients (53%) reported one or more adverse events. The relative numbers of patients reporting adverse events in the two groups were comparable (ADG 49%, SDG 56%). The most common adverse event (AE) was dry mouth, which was reported by 13 patients (35%) in the adjustable dose group and by 16 patients (37%) in the standard dose group. Other adverse events occurred at lower rates (Table 3) . The Fisher-Yates test showed no differences between the two dose groups with respect to adverse events.
Comparison of mean baseline and posttreatment clinical laboratory and cardiovascular values did not reveal any pathological changes or statistically significant differences between the two groups.
Discussion
To our knowledge, this study is the first specifically designed to investigate the influence of individual dose titration of trospium chloride on treatment success. Because trospium has already been proven efficacious in both overactive bladder and neurogenic detrusor overactivity [Andersson et al. 2002 , Füsgen and Hauri 2000 , Fröhlich et al. 2002 , Höfner et al. 2000 , Jünemann et al. 1999 , 2000 , Madersbacher et al. 1991 , Osca-Garcia et al. 1997 , Rudy et al. 2004 , Stöhrer et al. 1999 , Ulshöfer et al. 2001 , Zinner et al. 2004 , the study was designed as a randomized, double-blind, actively controlled trial in accordance with the relevant international guideline for dose response studies [ICH Topic E4 1994] . There are several reasons speaking against inclusion of a placebo group. Generally, treatment with placebo in this indication is poorly accepted by the patients and often makes patient recruitment difficult. Moreover, such a design would include a relevant bias by breaking blinding due to the increased leakage in the placebo group, and increase drop-out rate. On a fairly long-term basis inadequate treatment of patients with neurogenic detrusor overactivity may involve a certain risk for the upper urinary tract especially in paraplegic patients [Creasey 1994 , McGuire et al. 1997 .
Urodynamic assessment of study outcome in this special case allowed evaluation of dose response for the different dose levels within short intervals. Moreover, this allowed restricting exposure of the individual patients to the study medication, especially when treated at the higher dose levels [Homma et al. 2002] . In addition, evaluation of therapeutic response by means of urodynamic methods was justified in this study, as control of detrusor pressure may be of importance in patients with neurogenic detrusor overactivity in respect of avoidance of vesicoureteral reflux and upper urinary tract deterioration [Flood et al. 1994] .
The flexible dosing strategy is a close approximation to the "real-life" clinical situation, it allows treatment to be tailored to individual needs of the patients based on their individual response to the drug. Patients who are most responsive to the drug can therefore receive the lowest effective dose, thus reducing the risk of side effects and optimising the treatment outcome.
In this study, 72% of the patients in the standard dose group had achieved the desired improvement of urodynamic parameters by the end of the treatment period, although in 32.5% of these patients, dose escalation was assessed as necessary after Day 7. In the adjustable dose group, the daily dose was increased to 90 mg after Day 7 in 52.8% of the patients, and further dose escalation was carried out in 22.2% after Day 14. Nevertheless, 58% of patients in this dose group achieved treatment success, which, statistically, was not different from the results obtained in the standard dose group. Consequently, the results of this study suggest that, in the case of trospium chloride, dose escalation does not lead to a higher rate of treatment success in patients with neurogenic detrusor overactivity, i.e. the results suggest that the recommended standard dose of 3 × 15 mg is optimal for most patients. However, some patients less responsive to the drug may benefit in daily clinical situation from individual dose titration.
In both groups, the observed changes in urodynamic parameters corresponded to a reduction of bladder symptoms and a clear reduction of incontinence episodes, indicating that this method was suitable for assessment of treatment success in this study population. Furthermore, the fact that trospium chloride showed a fast onset of action in the first 7 days of treatment permitted an early assessment of treatment response in both groups.
In contrast to the present results, Stöhrer et al. [1998] found significant dose-dependent changes in urodynamic variables and symptoms using daily doses of 20, 40 and 80 mg trospium chloride in patients with neurogenic detrusor overactivity. However, their patients were randomized to fixed dose stages, and the number of patients in each dose group was small in comparison. Moreover, mean changes in urodynamic variables in the 80 mg dose group seem to be relatively low. Jünemann et al. [2000] investigated changes in maximum bladder capacity by treating patients with urge-syndrome with fixed doses of 40 and 80 mg/day. The increases at both dose levels (40 mg: 61 ml, 80 mg: 83 ml) were comparable to those observed in the present study. Contrary to the results described here, Jünemann and Füsgen [1999] found a dose-dependent increase in the percentage of patients reporting adverse events (40 mg: 51%, 80 mg: 64%), but also did not observe any serious adverse events.
Generally, extent and variation of trospium chloride plasma levels measured in this study corresponds to those observed in pharmacokinetic studies [Doroshyenko et al. 2005 , Schwantes and Topfmeier 1999 , but information on plasma levels during therapy are still missing until today. In the present trial, only a slight increase in trospium chloride plasma levels was observed in the small groups of patients treated with higher doses in the adjustable population. This corresponds to the fact that rate of adverse effects did not increase with the dose stage. Since patients were not asked to take their tablets before ingestion of food, the measured plasma levels may resemble the situation in clinical everyday-life, displaying relatively low steadystate levels.
Trospium chloride was well-tolerated in both dose groups during the 3-to 5-week treatment period, even at the 3-fold higher doses of 135 mg/day. This corresponds to the results of a previous study [Breuel et al. 1993] showing no difference in tolerance of single doses of trospium chloride at doses up to 120 mg. In the present study, rate of drop-outs due to adverse events was comparable in both groups (1 patient each with dysopia). Trospium chloride therefore appears to have a broader therapeutic window and a more stable tolerance/effect ratio than the other anticholinergic drugs.
Conclusion
In conclusion, daily doses of 3 × 15 mg trospium chloride appear to be effective in most patients with neurogenic detrusor overactivity. Generally, dose titration does not seem to benefit these patients. In this study, daily doses of up to 135 mg were well-tolerated and did not cause higher risks for the patient.
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